Custom service
Repetitive Immunizations Multiple Sites (RIMMS) Services
Monoclonal antibodies in six weeks, from mice that never see a long protocol.
A conventional monoclonal campaign is paced by the calendar, not by the biology. Four immunisations spaced three weeks apart, a test bleed, a fusion, and eight to twelve weeks have gone before the first positive supernatant is screened. RIMMS compresses that by treating the draining lymph node as the organ of interest: antigen is delivered to multiple intradermal and subcutaneous sites every third day, and the nodes that drain them are harvested while the germinal centre reaction is at its height.
The anatomical logic is simple. Each injection site drains to a defined node — popliteal, inguinal, brachial, cervical — and by spreading the antigen across six to eight sites, several independent node reactions mature in parallel. Fusion efficiency from these nodes is markedly higher than from a spleen collected weeks after the last boost, because the antigen-specific blasts are still present in the node rather than having dispersed.
The result is a serviceable monoclonal antibody panel in five to six weeks, with the caveat that affinity maturation is truncated. RIMMS returns antibodies of the IgM and early IgG classes more often than a long protocol does, and the best clones are usually good reagents rather than therapeutic leads.
Service Highlights
Where it fits
RIMMS is the right route when the reagent is needed quickly and the antigen is well characterised: a sandwich pair for a new ELISA, a capture antibody for a lateral flow strip, a detection antibody against a tag or a small domain. It is also useful for antigens that are available only in microgram amounts, since the total dose per animal is a fraction of a conventional protocol.
It is a poor route for therapeutic discovery, where affinity maturation and clonal selection need time, and for antigens that require a long prime–boost interval to break tolerance. In those cases the slower protocol returns better antibodies, and we will recommend it.
Documentation and QC
Each fusion is reported with plate-level screening data, the number of parent positives, isotype distribution and subcloning history. Hybridoma cultures are tested for mycoplasma before freezing, and each frozen vial is accompanied by a passage number and a viability record.
Frequently asked questions
How does RIMMS compare with a standard protocol in affinity?
Antibodies tend to be of lower affinity on average because the maturation window is short. For reagent use this rarely matters; for KD below 10⁻⁹ M we would run a conventional protocol or follow with affinity maturation.
How much antigen is needed?
100–200 µg per mouse in total, split across all injections. Conjugation to KLH or OVA is often necessary below 20 kDa, and we can do that in house.
Can RIMMS be run in rats or rabbits?
The multiple-site principle transfers, but the timing and node yield are less predictable outside mice. For rabbit monoclonals we usually recommend B cell sorting or a standard protocol.
Send the antigen and the assay you intend to screen with. If a six-week RIMMS campaign cannot produce the affinity you need, we will say so before the first injection.
Service Highlights
- Compressed calendar. Five to six weeks from antigen hand-off to validated hybridoma supernatants, against ten to fourteen for a standard protocol.
- Multiple draining nodes. Six to eight injection sites, four node groups harvested separately and fused in parallel.
- Adjuvant matched to antigen. TiterMax, RIBI or incomplete Freund's depending on antigen solubility, with CpG and poly(I:C) as aqueous alternatives.
- Fusion-ready timing. Nodes are taken 24–48 hours after the final boost, when the plasmablast population is maximal.
- Screening by your assay. ELISA, cell-based FACS or functional readout, run on the first 96-well plate rather than after subcloning.
- Rapid rescues. Positive wells are expanded and frozen immediately, so a clone is never lost to contamination or overgrowth.
How the work runs
Antigen preparation review
Purity, endotoxin and adjuvant compatibility are checked. Particulate and aggregated antigens perform best; soluble monomers are coupled to a carrier or formulated in RIBI.
Immunisation series
Six to eight sites per mouse, four to six rounds at three-day intervals, equal antigen dose each time. Two to three mice are run in parallel.
Node harvest
Popliteal, inguinal, brachial and cervical nodes are collected 24–48 hours after the last injection and processed separately.
Fusion and selection
PEG fusion with SP2/0, HAT selection, and plating into 96-well plates at a density that keeps one clone per well in most positives.
Screening and subcloning
Supernatants are screened against the immunogen and a carrier-only control; positives go through two limiting-dilution rounds.
Isotyping and scale-up
Isotype and light chain are determined, then the clone is expanded in vitro or as ascites according to the volume you need.
Specifications & timeline
- Timeline
- 5–6 weeks — to hybridoma supernatant
- Injection sites
- 6–8 — draining lymph nodes targeted
- Boosts
- 4–6 — at 3-day intervals
- Species
- BALB/c and C57BL/6 mice; other strains on request
- Timeline
- 5–6 weeks: immunisation 3 weeks, fusion and screening 2–3 weeks
- Antigen amount
- 100–200 µg total per mouse, carrier-conjugated if below 20 kDa
- Screening formats
- ELISA, flow cytometry, dot blot, functional assays
- Deliverables
- 2–5 subcloned hybridomas, isotype report, 1–5 mL supernatant per clone, frozen vials
- Scale-up
- In vitro culture to 100 mg, or ascites to 5–10 mL per mouse
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.